HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830
Question
HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830
Direct answer
HUTCHMED has dosed the first patient in its Phase Ia trial testing HMPL-A830 for the treatment of advanced solid tumors. The candidate is a first-in-class antibody conjugate designed to target both KRAS and EGFR pathways concurrently. The program is being developed under an exclusive collaboration and licensing agreement with GSK. Initial safety, tolerability, and pharmacokinetic readout windows will define next-phase dose expansion plans. — bullish pressure on GSK.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-28
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830”, revision 1, evidence through 2026-09-28. https://marketontology.com/catalysts/2026-09-28/hutchmed-and-gsk-dose-first-patient-in-phase-ia-trial-of-kras-egfr-conjugate-hmp-26a12b
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| GSK | ▲Bull | 1–3 months | Policy Shift | 72 |
HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830
HUTCHMED has dosed the first patient in its Phase Ia trial testing HMPL-A830 for the treatment of advanced solid tumors. The candidate is a first-in-class antibody conjugate designed to target both KRAS and EGFR pathways concurrently. The program is being developed under an exclusive collaboration and licensing agreement with GSK. Initial safety, tolerability, and pharmacokinetic readout windows will define next-phase dose expansion plans. — bullish pressure on GSK.
HUTCHMED has dosed the first patient in its Phase Ia trial testing HMPL-A830 for the treatment of advanced solid tumors. The candidate is a first-in-class antibody conjugate designed to target both KRAS and EGFR pathways concurrently. The program is being developed under an exclusive collaboration and licensing agreement with GSK. Initial safety, tolerability, and pharmacokinetic readout windows will define next-phase dose expansion plans.
- SummaryHUTCHMED has dosed the first patient in its Phase Ia trial testing HMPL-A830 for the treatment of advanced solid tumors. The candidate is a first-in-class antibody conjugate designed to target both KRAS and EGFR pathways concurrently. The program is being developed under an exclusive collaboration and licensing agreement with GSK. Initial safety, tolerability, and pharmacokinetic readout windows will define next-phase dose expansion plans.
- GSKDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- GSK closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- GSK price vs. pre-event level
- GSK volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR conjugate license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-10-21GSK gains ex-China rights to HMPL-A830GSK
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed a KRAS-EGFR license with GSK outside ChinaGSK HCM
- 2026-09-28HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830GSK HCM+0.14%
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK HCM+0.14%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.